Interstitial lung disease (ILD) Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Interstitial Lung Disease (ILD) Market is Segmented By Disease Type (Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonitis, Hypersensitivity Pneumonitis, Cryptogenic Organizing Pneumonia (COP), Acute Interstitial Pneumonitis, Others), By Drug Type (Oral Corticosteroids, Immune Suppressing, Anti-Fibrotic Medication, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Overview

Interstitial lung disease (ILD) Market is expected to grow at a CAGR of 6.1% during the forecast period 2024-2031

Interstitial lung disease is caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Scarring of the lungs is usually irreversible once it develops. A dry cough is one of the symptoms. Short breath can occur at rest or after effort, and treatment varies depending on the underlying reason. However, steroids are frequently used.

Market Summary

To know more Insights Download Sample

Market Dynamics

Advancements in the diagnosis, prognosis, and treatment response for progressive fibrosing interstitial lung disease are expected to drive market growth.

Idiopathic pulmonary fibrosis (IPF) is the most common progressive fibrosing ILD (PF-ILD); PF-ILD affects many patients with other ILD subtypes. Biomarker investigation to date has identified several molecular markers that predict relevant ILD endpoints, including disease presence, prognosis, and treatment response. Recent research has shown that modeling plasma biomarkers in aggregate have more potential. When modeled with clinical features, Doyle et al. found that matrix metalloproteinase 7 (MMP-7), pulmonary and activation-related chemokine (PARC), and surfactant protein D (SP-D) accurately predicted ILD in individuals with rheumatoid arthritis (RA). White and colleagues used a similar approach to create and validate a protein prediction score to identify IPF from healthy controls and most alternative ILDs, utilizing plasma MMP-7, SP-D, and osteopontin concentrations.

Additionally, Sanders et colleagues. recently demonstrated that biomarkers hold potential for detecting early ILD, also known as interstitial lung abnormalities (ILAs). GDF15 and four additional plasma biomarkers are elevated in community-dwelling persons with ILAs, with GDF15 being verified in a separate cohort. These findings suggest that plasma biomarkers may one day be used to screen for ILD without intrusive testing. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Lack of awareness associated with interstitial lung disease and side effects associated with the drugs are the factors the market is expected to get hampered in the forecast period.

COVID-19 Impact Analysis on Market

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Patients with ILD are more susceptible to COVID-19 and have a higher risk of developing the severe disease than those who do not. In one study, patients with COVID-19 ILD had a 49 percent overall mortality rate; poor lung function and obesity increased the risk of death. In another study, patients with ILD and COVID-19 had a higher risk of severe illness and death than age, sex and race-matched controls without ILD. Nonsurvivors in this small group are older, had lower DLCO, and had a higher proportion of a typical interstitial pneumonia pattern on computed tomography (CT) scans; earlier ILD-directed therapy did not affect outcomes.

Moreover, the lack of objective indicators of disease development, such as pulmonary function testing (PFT) and 6-minute walk (6MW) tests, led to inadequate clinical assessment during Coronavirus. Additionally, during the pandemic, rapid changes in global health disturbed the usual care of patients with ILD. Healthcare institutions have evolved several practices to counteract these consequences, including delivering care to patients via telemedicine visits and nurse home visits. Thus, the above statements affected the market, and the market is expected to boost in the forecast period.

Market Segmentation Analysis

Anti-Fibrotic Medication segment is expected to hold the largest market share in interstitial lung disease (ILD) market

The anti-fibrotic medication segment is expected to dominate in 2021. The segment benefits because it is shown in clinical trials to slow down the rate of fibrosis or scarring in the lungs. These drugs are approved for patients with mild, moderate and severe IPF. For instance, the US Food and Drug Administration has approved two drugs to treat persons with idiopathic pulmonary fibrosis (IPF). People with scleroderma-related ILD or other kinds of progressive pulmonary fibrosis can also use nintedanib (Ofev) and Esbriet (pirfenidone). Therefore, it has increased the clinical trials and product approvals. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Market Geographical Share

North America region holds the largest market share in the global interstitial lung disease (ILD) market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of Pulmonary Fibrosis, rising geriatric population, well-established infrastructure, increasing clinical trials and number of product approvals in the region are some factors the market is expected to boost in the forecast period. For instance, Idiopathic pulmonary fibrosis is more common than we once thought, with up to 207,000 people affected in the United States and about 58,000 new cases diagnosed each year. It is more common in men than women and mostly affects people over 50 years of age. Moreover, The U.S. Food and Drug Administration (FDA) approved Actemra/RoActemra (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options, in March 2021, according to F. Hoffmann-La Roche Ltd, a biotech company. The first biologic drug approved by the US FDA for treating the condition is Actemra/RoActemra. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Companies and Competitive Landscape

Major key players in the interstitial lung disease (ILD) market are Horizon Pharma USA, Inc., Novartis Pharmaceuticals Corporation, Genentech, Inc., Roche Laboratories Inc., Teva Pharmaceuticals USA, Inc., Prometheus Laboratories Inc., Amneal Pharmaceuticals LLC, Boehringer Ingelheim Pharmaceuticals, Inc and Amgen Inc.                   

Genentech, Inc.:

Overview:

F. Hoffmann-La Roche Ltd is the parent company of Genentech Inc., a biotechnology company based in the United States that became a subsidiary of Roche in 2009. The company is dedicated to pioneering science to discover and develop medicines for people suffering from serious and life-threatening diseases. In the United States, Roche and Genentech merged their pharmaceutical operations. The Genentech campus in South San Francisco is now the headquarters for Roche's pharmaceutical operations in the United States. Genentech Research and Early Development is a separate entity within Roche. Roche Holding Ltd. owns 66 percent of Genentech but allows it to operate independently. Genentech discovers, develops, manufactures, and sells human pharmaceuticals to meet critical medical needs.

­Product Portfolio:

CELLCEPT (MYCOPHENOLATE MOFETIL): Mycophenolate is used to reduce inflammation, which can contribute to your symptoms of breathlessness and reduce your ability to exercise.